Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Muirhead, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muirhead, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 51-56
© 2001 European Renal Association-European Dialysis and Transplant Association

The rationale for early management of chronic renal insufficiency

Norman Muirhead

University of Western Ontario, London, Ontario, Canada

Abstract

Several strategies are available to delay progression of renal disease and the development of associated co-morbidities. Hypertension is a strong independent risk factor for end-stage renal disease (ESRD) and there is consensus that blood pressure (BP) management is an important aspect of care in patients with chronic renal insufficiency (CRI). Clinical studies have shown that angiotensin-converting enzyme (ACE) inhibitors have renoprotective properties, independent of their antihypertensive effects, which can delay the onset of ESRD. Studies have also shown that intensive therapy of both type 1 and type 2 diabetes patients, to give near normal blood glucose concentrations, can reduce the incidence of progressive clinical proteinuria and may, therefore, protect against ESRD. Additionally, data are emerging that treatment of renal anaemia with epoetin can reduce mortality and delay the onset of dialysis in CRI patients, but these encouraging results need to be confirmed in large prospective studies. In conclusion, control of BP and hyperglycaemia, as well as use of ACE inhibitors and anaemia treatment, all have potential in delaying the progression of CRI or improving patient outcomes. If benefit is proven in future studies, these strategies will be most effective if implemented early in the course of CRI.

Keywords: ACE inhibitors; anaemia; chronic renal insufficiency; diabetes; hyperlipidaemia; hypertension

Notes

Correspondence and offprint requests to: Dr Norman Muirhead, University of Western Ontario, London Health Science Centre, 5339 Windermere Road, London, Ontario N6A 5A5, Canada.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
J. M. Flack, R. Peters, T. Shafi, H. Alrefai, S. A. Nasser, and E. Crook
Prevention of Hypertension and Its Complications: Theoretical Basis and Guidelines for Treatment
J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S92 - 98.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. Ueda, E. Ishimura, T. Shoji, M. Emoto, T. Morioka, N. Matsumoto, S. Fukumoto, T. Miki, M. Inaba, and Y. Nishizawa
Factors Affecting Progression of Renal Failure in Patients With Type 2 Diabetes
Diabetes Care, May 1, 2003; 26(5): 1530 - 1534.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.